Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 19/20 | 0.67 |
| ▸ | PSEN2 | P49810 | 19/20 | 0.67 |
| ▸ | APH1B | Q8WW43 | 19/20 | 0.67 |
| ▸ | NCSTN | Q92542 | 19/20 | 0.67 |
| ▸ | APH1A | Q96BI3 | 19/20 | 0.67 |
| ▸ | PSENEN | Q9NZ42 | 19/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18615039 | 1.00 | PSEN1 (0.67) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18636341 | 1.00 | PSEN1 (0.67) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18615041 | 1.00 | PSEN1 (0.67) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18636422 | 0.89 | PSEN1 (0.70) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18615139 | 0.89 | PSEN1 (0.70) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21887521 | 0.89 | PSEN1 (0.70) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18615138 | 0.89 | PSEN1 (0.70) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21886895 | 0.87 | PSEN1 (0.66) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21887048 | 0.84 | PSEN1 (0.65) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18636240 | 0.84 | PSEN1 (0.65) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604517-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604517-B2 | Bridged piperidine derivatives | HPGDS, APP, PSEN1 | PSEN1 3/4885PSEN2 11/4885APH1B 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.